Grant of Share Options

January 27, 2022
PDF Version
RNS Number : 8956Z
Renalytix PLC
27 January 2022
 

 

 

Renalytix plc

("Renalytix" or the "Company")

 

Grant of Share Options

 

New York and SALT LAKE CITY, January 27, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total of 40,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to Daniel Levangie, a Non-Executive Director of the Company.

 

The Share Options, which have been issued in line with the Company's existing share option plan, have  an exercise price of £4.95 per share, being the closing mid-market price on 26 January 2022. One quarter of the Share Options vest 12 months from the date of grant with one twelfth vesting quarterly after that, subject to Mr. Levangie remaining a Non-Executive Director of the Company. The Share Options have typical acceleration provisions in the event of a change of control of Renalytix.

 

For further information, please contact:

 

Renalytix plc 

www.renalytix.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore 




Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams




Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303



CapComm Partners


Peter DeNardo

 

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name 

 

 

Daniel Levangie

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name 

 

 

Renalytix plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of 0.25 pence each in the Company



Identification code

GB00BYWL4Y04

 


b)

 

Nature of the transaction

 

 

Grant of options over shares

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 


 

£4.95

40,000

 


 

 

 

 

d)

 

Aggregated information

 

 

40,000



- Aggregated volume

£198,000



- Price




e)

 

Date of the transaction

 

 

27 January 2022

f)

 

Place of the transaction

 

 

Outside of trading venue - off market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEDLFLLFLFBBZ